Actively Recruiting
Phase I Study Evaluating Inhaled Antibiotics Combined with Pembrolizumab for Advanced Non-Small Cell Lung Cancer
Led by National Cancer Institute (NCI) · Updated on 2026-10-16
23
Participants Needed
1
Research Sites
52 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying advanced non-small cell lung cancer NSCLC, a serious condition that can be difficult to treat and often fatal. This study aims to evaluate whether adding two inhaled antibiotics, aztreonam and vancomycin, to a standard cancer treatment called pembrolizumab can improve outcomes for people whose cancer has returned or worsened after prior therapy and cannot be treated with surgery. The trial is a phase I, open-label, single-arm study focused on safety and feasibility. Participants will receive six cycles of treatment, each lasting 21 days. On the first day of each cycle, pembrolizumab will be given intravenously by a needle in the arm. During cycles 1, 3, and 5, participants will use inhaled aztreonam up to three times daily and inhaled vancomycin one or two times daily at home, using a device that produces a fine mist. There are two dose levels for the inhaled antibiotics, with a possible dose reduction if side effects occur. The antibiotics are not taken during cycles 2, 4, and 6. Participants will undergo screening with physical exams, blood tests, lung function tests, imaging scans, and possibly tumor biopsies before starting treatment. Similar biopsies and tests will be repeated halfway through and after completing therapy. After treatment, follow-up visits will continue for one year to monitor safety and the studys main outcomes, including dose limiting toxicities. The total participation time includes screening, six treatment cycles, and one year of follow-up.
CONDITIONS
Brief Title
Study of Aerosolized Antibiotics and Pembrolizumab in Advanced Non-small Cell Lung Cancer
Research Team
S
Shannon G Swift, R.N.
C
Chen Zhao, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here